
Please try another search
CalciMedica, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. The company’s lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated calcium (CRAC) channel inhibitors for the treatment of acute pancreatitis, asparaginase-induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia. It also develops Auxora for the treatment of acute ulcerative colitis, traumatic brain injury, and allergic asthma; and oral CRAC channel inhibitors for use in chronic inflammatory indications. The company is based in La Jolla, California.
Name | Age | Since | Title |
---|---|---|---|
A. Rachel Leheny | 62 | 2019 | CEO & Director |
Eric W. Roberts | 61 | 2020 | Chief Business Officer & Vice Chairman of the Board |
Robert N. Wilson | 84 | 2020 | Independent Chairman of the Board |
Allan J. Lee Shaw | 61 | 2021 | Independent Director |
Fred A. Middleton | 76 | 2020 | Independent Director |
Frederic Guerard | 53 | 2019 | Director |
Alan Glicklich | 62 | 2025 | Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review